The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Miglustat Dipharma miglustat Generic | Dipharma Arzneimittel GmbH | Gaucher Disease | 🇪🇺 EU 2019-02-18 | Order → |
| Mulpleo (previously Lusutrombopag Shionogi) lusutrombopag | Shionogi B.V. | Thrombocytopenia | 🇪🇺 EU 2019-02-18 | Order → |
| Rizmoic naldemedine | Shionogi B.V. | Constipation | 🇪🇺 EU 2019-02-18 | Order → |
| Vantobra (previously Tobramycin PARI) tobramycin | Pari Pharma GmbH | Respiratory Tract Infections; Cystic Fibrosis | 🇪🇺 EU 2019-02-18 | Order → |
| Besremi ropeginterferon alfa-2b | AOP Orphan Pharmaceuticals GmbH | Polycythemia Vera | 🇪🇺 EU 2019-02-15 | Order → |
| Zirabev bevacizumab BiosimilarAdditional monitoring | Pfizer Europe MA EEIG | Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms | 🇪🇺 EU 2019-02-14 | Order → |
| Erleada apalutamide | Janssen-Cilag International NV | Prostatic Neoplasms | 🇪🇺 EU 2019-01-14 | Order → |
| Ghryvelin (previously Macimorelin Aeterna Zentaris) macimorelin Additional monitoring | Atnahs Pharma Netherlands B.V. | Diagnostic Techniques, Endocrine | 🇪🇺 EU 2019-01-11 | Order → |
| Silodosin Recordati silodosin Generic | Recordati Ireland Ltd | Prostatic Hyperplasia | 🇪🇺 EU 2019-01-07 | Order → |
| Bevespi Aerosphere glycopyrronium;formoterol fumarate dihydrate | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2018-12-18 | Order → |
| Namuscla Mexiletine Orphan | Lupin Europe GmbH | Myotonic Disorders | 🇪🇺 EU 2018-12-18 | Order → |
| Dengvaxia dengue tetravalent vaccine (live, attenuated) | Sanofi Winthrop Industrie | Dengue | 🇪🇺 EU 2018-12-12 | Order → |
| Flucelvax Tetra influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2018-12-12 | Order → |
| Ogivri trastuzumab Biosimilar | Biosimilar Collaborations Ireland Limited | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2018-12-12 | Order → |
| Alunbrig brigatinib | Takeda Pharma A/S | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2018-11-22 | Order → |
| Delstrigo doravirine;lamivudine;tenofovir disoproxil | Merck Sharp & Dohme B.V. | HIV Infections | 🇪🇺 EU 2018-11-22 | Order → |
| Jivi damoctocog alfa pegol | Bayer AG | Hemophilia A | 🇪🇺 EU 2018-11-22 | Order → |
| Luxturna voretigene neparvovec OrphanATMPAdditional monitoring | Novartis Europharm Limited | Leber Congenital Amaurosis; Retinitis Pigmentosa | 🇪🇺 EU 2018-11-22 | Order → |
| Pifeltro doravirine | Merck Sharp & Dohme B.V. | HIV Infections | 🇪🇺 EU 2018-11-22 | Order → |
| Poteligeo mogamulizumab Orphan | Kyowa Kirin Holdings B.V. | Sezary Syndrome; Mycosis Fungoides | 🇪🇺 EU 2018-11-22 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.